$10.01
-0.01 (-0.05%)
DMII News6 articles
Teva Surges 11% as Branded Drugs Drive Q1 Beat, Emalex Deal Adds Tourette Candidate
Teva beat Q1 estimates with adjusted EPS of $0.53 on $3.98B revenue, as branded drug sales surged 41%. Shares rose 11% on the news.
Biogen Acquires Apellis in $5.6B Deal, Adding Eye and Kidney Drugs
Biogen has entered a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion. The deal includes a $41 per share cash offer plus contingent value rights.
Vertex Shares Slide on Updated Safety Warnings for CF Drugs
Vertex Pharmaceuticals shares declined 4.6% to $433.07 following updated U.S. safety labels for its cystic fibrosis drugs citing serious neuropsychiatric events. The company maintains its 2026 revenue outlook remains heavily dependent on CF treatments.
Hims & Hers Shares Extend Decline Amid Novo Nordisk Patent Lawsuit Over Compounded Weight-Loss Drugs
Hims & Hers Health stock fell another 5.6% as Novo Nordisk filed a patent lawsuit seeking to block compounded versions of Wegovy, tightening regulatory pressure on the online health provider's GLP-1 offerings.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly's stock rose 3.7% after the FDA warned Hims & Hers to halt sales of a non-approved compounded GLP-1 weight-loss pill, signaling a regulatory clampdown that may support pricing for branded obesity drugs.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.